Drug Trial Radar · NCT04354246
COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Mar 31, 2020
Primary completion
Apr 1, 2026
Study completion Apr 1, 2026
Sponsor
- Lead sponsor
- Compugen LtdIndustry
- Sponsor type
- Industry
- First posted
- Apr 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
Conditions
- Advanced Cancer
- Ovarian Cancer
- Lung Cancer
- Colon Cancer
- Plasma Cell Neoplasm
- Multiple Myeloma
- HNSCC
- Microsatellite Stable Colorectal Carcinoma
- MSS-CRC
Interventions
Dose escalation: COM902 monotherapy.Drug
COM902 monotherapy administered IV every 3 weeks in sequential dose escalation doses in cohorts of subjects.
Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)Combination product
Both study drugs will be evaluated at the RDFE for assessment of safety and tolerability. All study drugs will be administered IV every 3 weeks.
Cohort expansion: COM902 (RDFE) monotherapy.Drug
COM902 monotherapy (RDFE) in subjects with multiple myeloma. COM902 will be administered IV every 3 weeks.
Cohort expansion: COM902 in combination with COM701 (both at the RDFE).Drug
COM902 in combination with COM701 (both at RDFE) in subjects with select tumor types who have exhausted standard treatment - HNSCC, CRC (MSS), NSCLC. All study drugs will be administered IV every 3 weeks.
Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.Combination product
Triplet combination of COM902 + COM701 + Pembrolizumab administered IV every 3 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The safety and tolerability of COM902 monotherapy and in combination with COM701.Time frame: DLT evaluation window in the 1st cycle (21 Days).
- To identify the maximum tolerated dose (MTD) and/or recommended dose for expansion of COM902 monotherapy and in combination with COM701.Time frame: 18 months.
- To characterize the pharmacokinetic (PK) profile of COM902 as monotherapy and in combination with COM701.Time frame: 18 months.
- Evaluation of safety and tolerability of the Triplet combination (COM902 + COM701 + Pembrolizumab).Time frame: 18 months.
- Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).Time frame: 18 months.
- Evaluation of the PK profile of the Triplet combination (COM902 + COM701 + Pembrolizumab).Time frame: 18 months.
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Florida Cancer Specialists
Sarasota, Florida
Massachusetts General Hospital.
Boston, Massachusetts
START Midwest.
Grand Rapids, Michigan
The Ohio State University Comprehensive Cancer Center.
Columbus, Ohio
The University of Tennessee WEST Cancer Center.
Memphis, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson Cancer Center.
Houston, Texas
The START Center for Cancer Care.
San Antonio, Texas
Froedtert & Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.